CGEMNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Cullinan Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$13.98+1.05 (+8.12%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Margins need revenue and profit figures
This company does not report the lines needed to calculate margins.
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
7 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2019 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -35.0% | -44.0% | |
| Return on assets | – | – | -41.1% | |
| Current ratio | – | 14.82 | 10.25 | |
| Diluted shares | – | 20M | – |
Where the cash went
Fiscal 2021 to 2025, five years combined
Cullinan Therapeutics generated $625.43M from operations and spent $1.39M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$625.43M
Used
$1.39M
Capital expenditure$1.39M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-346.1%
×Asset turnover0.06×
×Equity multiplier1.04×
=Return on equity, FY2021-21.0%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2021 | -346.1% | 0.06× | 1.04× | -21.0% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
1of 5 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$219.88M
- Cash generatingOperating cash flow above zero-$175.75M
- Return on assets improvedROA up on the prior year-34.6% → -35.4%
- Earnings backed by cashOperating cash flow above net income-$175.75M vs -$219.88M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose13.53 → 10.25
- No dilutionShare count did not rise– → –
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → –